Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jazz Pharmaceuticals plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jazz Pharmaceuticals plc's regulatory disclosures and financial reporting.
Jazz Pharmaceuticals (JAZZ) has filed a Form 144 indicating that Chairman & CEO Bruce C. Cozadd intends to sell up to 9,000 common shares through Merrill Lynch on or about 1 Aug 2025. Based on the reference price in the filing, the sale is valued at approximately $1.10 million, equal to ~0.01% of the company’s 61.6 million shares outstanding.
The shares were acquired via equity-compensation grants made between December 2021 and February 2022. Over the past three months Cozadd has already sold 2,500 shares for gross proceeds of $276.6 k. The filer certifies under Rule 144 that he possesses no undisclosed material adverse information.
While such sales are common for liquidity or tax purposes, investors often view continued insider selling—especially by the CEO—as a potential signal of tempered confidence. Market watchers may track any additional Form 4 filings or 10b5-1 plan disclosures for context.
Jazz Pharmaceuticals plc (JAZZ) has issued a DEFA14A supplement to its 2025 proxy materials outlining a planned CEO succession and related compensation adjustments.
- Leadership transition: President & COO Renee Gala will become President & Chief Executive Officer on 11 Aug 2025. Current CEO Bruce Cozadd will remain until that date, then serve in a transition role through 12 Sep 2025 before retiring while continuing as Board Chair.
- Board expansion: Board size increases from 12 to 13 seats; Ms. Gala will join as a Class I director with a term expiring in 2027.
- Compensation changes: Ms. Gala’s annual base salary rises to $1.2 million (from $0.9 million) and her target cash bonus to 110% of salary (from 80%), effective 11 Aug 2025.
- Equity awards: One-time promotion grant valued at ~$6.5 million (33% RSUs, 67% PSUs) in addition to her previously granted 2025 annual equity award of ~$6 million.
- Enhanced severance: Cash severance on involuntary termination without cause (outside a change-in-control period) increases to 150% of base salary plus up to 18 months of COBRA premiums (previously 100% salary and 12 months premiums).
- Voting impact: No changes to the proposals or proxy card for the 24 Jul 2025 AGM; shareholders are encouraged to review both the original proxy and this supplement.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) disclosed in an 8-K that its Board appointed current President & COO Renee Gala as President & Chief Executive Officer effective 11 Aug 2025. The Board will expand from 12 to 13 members and seat Gala as a Class I director through the 2027 AGM. Outgoing CEO Bruce Cozadd will remain CEO until 11 Aug 2025, shift to a transition role until 12 Sep 2025, then retire while continuing as non-executive Chair.
Gala’s compensation package was revised: base salary rises 33 % to $1.2 million; target annual bonus increases to 110 % of salary (from 80 %). She will also receive a one-time $6.5 million promotion equity grant (33 % RSUs vesting annually over four years; 67 % PSUs tied to 2025 performance metrics) on top of her previously granted $6 million 2025 annual equity award.
Severance protections were enhanced: in an involuntary termination without cause outside a change-in-control window, Gala is now entitled to a lump-sum payment equal to 150 % of base salary (previously 100 %) and up to 18 months of company-paid COBRA premiums (previously 12 months).
No financial metrics, earnings guidance, or strategic updates were included. A confirming press release (Exhibit 99.1) was furnished under Item 7.01.